[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

08/12/2022

Less than a minute

2022.08.12 11:26

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
FILE PHOTO: Zantac heartburn pills are seen in this picture illustration taken October 1, 2019. REUTERS/Brendan McDermid/Illustration/File Photo

LONDON (Reuters) – Shares in GSK, Sanofi (NASDAQ:SNY)

The companies’ share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug’s withdrawal from markets in 2019 and 2020. The first U.S. trial is expected to start this month.

Source

08/12/2022

Less than a minute